Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics


Aclaris Therapeutics, Inc. (ACRS)

Today's Latest Price: $18.83 USD

12.95 (220.24%)

Updated Jan 19 4:00pm

Add ACRS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ACRS Stock Summary

  • With a year-over-year growth in debt of -63.35%, Aclaris Therapeutics Inc's debt growth rate surpasses just 4.43% of about US stocks.
  • As for revenue growth, note that ACRS's revenue has grown -61.45% over the past 12 months; that beats the revenue growth of just 3.47% of US companies in our set.
  • In terms of volatility of its share price, ACRS is more volatile than 94.93% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Aclaris Therapeutics Inc, a group of peers worth examining would be RESN, MRKR, BCDA, XAIR, and CUE.
  • ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to www.aclaristx.com.

ACRS Stock Price Chart Interactive Chart >

Price chart for ACRS

ACRS Price/Volume Stats

Current price $18.83 52-week high $19.95
Prev. close $5.88 52-week low $0.70
Day low $13.29 Volume 114,362,100
Day high $19.95 Avg. volume 10,760,209
50-day MA $5.06 Dividend yield N/A
200-day MA $2.88 Market Cap 808.16M

Aclaris Therapeutics, Inc. (ACRS) Company Bio


Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.


ACRS Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRS Latest Social Stream


Loading social stream, please wait...

View Full ACRS Social Stream

Latest ACRS News From Around the Web

Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.

The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia ...

Benzinga | December 29, 2020

Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Yahoo | December 29, 2020

Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options

Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.

Yahoo | December 23, 2020

Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?

NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | December 17, 2020

Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing…

GlobeNewswire | November 16, 2020

Read More 'ACRS' Stories Here

ACRS Price Returns

1-mo 241.12%
3-mo 343.06%
6-mo 740.63%
1-year N/A
3-year -22.83%
5-year -16.53%
YTD 191.04%
2020 242.33%
2019 -74.42%
2018 -70.03%
2017 -9.14%
2016 0.74%

Continue Researching ACRS

Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:

Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7148 seconds.